X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs CIPLA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA CIPLA SUN PHARMA/
CIPLA
 
P/E (TTM) x 15.3 44.1 34.8% View Chart
P/BV x 3.6 3.6 99.2% View Chart
Dividend Yield % 0.2 0.4 60.2%  

Financials

 SUN PHARMA   CIPLA
EQUITY SHARE DATA
    SUN PHARMA
Mar-16
CIPLA
Mar-17
SUN PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,201622 193.1%   
Low Rs706458 154.1%   
Sales per share (Unadj.) Rs117.5181.9 64.6%  
Earnings per share (Unadj.) Rs19.612.9 152.3%  
Cash flow per share (Unadj.) Rs23.829.3 81.2%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.10.4 28.3%  
Book value per share (Unadj.) Rs130.5155.7 83.8%  
Shares outstanding (eoy) m2,406.60804.51 299.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x8.13.0 273.3%   
Avg P/E ratio x48.742.0 116.0%  
P/CF ratio (eoy) x40.118.4 217.4%  
Price / Book Value ratio x7.33.5 210.6%  
Dividend payout %5.115.5 32.8%   
Avg Mkt Cap Rs m2,294,813434,516 528.1%   
No. of employees `00014.723.0 64.0%   
Total wages/salary Rs m47,97126,338 182.1%   
Avg. sales/employee Rs Th19,169.86,349.1 301.9%   
Avg. wages/employee Rs Th3,253.01,143.0 284.6%   
Avg. net profit/employee Rs Th3,197.9449.3 711.7%   
INCOME DATA
Net Sales Rs m282,697146,302 193.2%  
Other income Rs m6,1702,287 269.8%   
Total revenues Rs m288,867148,589 194.4%   
Gross profit Rs m83,23924,758 336.2%  
Depreciation Rs m10,13513,229 76.6%   
Interest Rs m4,7691,594 299.2%   
Profit before tax Rs m74,50512,222 609.6%   
Minority Interest Rs m-11,1260-   
Prior Period Items Rs m-19-70 26.8%   
Extraordinary Inc (Exp) Rs m-6,8520-   
Tax Rs m9,3491,798 520.1%   
Profit after tax Rs m47,15910,354 455.5%  
Gross profit margin %29.416.9 174.0%  
Effective tax rate %12.514.7 85.3%   
Net profit margin %16.77.1 235.7%  
BALANCE SHEET DATA
Current assets Rs m308,64687,370 353.3%   
Current liabilities Rs m132,47733,081 400.5%   
Net working cap to sales %62.337.1 167.9%  
Current ratio x2.32.6 88.2%  
Inventory Days Days8387 95.4%  
Debtors Days Days8862 140.8%  
Net fixed assets Rs m133,606111,567 119.8%   
Share capital Rs m2,4071,609 149.6%   
"Free" reserves Rs m266,909123,645 215.9%   
Net worth Rs m314,042125,254 250.7%   
Long term debt Rs m31,16736,454 85.5%   
Total assets Rs m542,196209,532 258.8%  
Interest coverage x16.68.7 191.8%   
Debt to equity ratio x0.10.3 34.1%  
Sales to assets ratio x0.50.7 74.7%   
Return on assets %9.65.7 168.0%  
Return on equity %15.08.3 181.7%  
Return on capital %17.88.5 208.8%  
Exports to sales %14.034.2 40.9%   
Imports to sales %3.18.3 37.7%   
Exports (fob) Rs m39,57250,050 79.1%   
Imports (cif) Rs m8,88212,203 72.8%   
Fx inflow Rs m42,17151,066 82.6%   
Fx outflow Rs m21,58317,678 122.1%   
Net fx Rs m20,58833,388 61.7%   
CASH FLOW
From Operations Rs m67,69423,824 284.1%  
From Investments Rs m-44,549-13,127 339.4%  
From Financial Activity Rs m-19,243-13,239 145.4%  
Net Cashflow Rs m3,902-2,478 -157.4%  

Share Holding

Indian Promoters % 63.7 16.0 398.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 5.1 12.2 42.0%  
FIIs % 23.0 23.7 97.0%  
ADR/GDR % 0.0 1.1 -  
Free float % 8.3 26.2 31.7%  
Shareholders   133,026 161,166 82.5%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ALEMBIC LTD  SHASUN PHARMA  PFIZER  FDC LTD.  AUROBINDO PHARMA  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS